Table 3.

Demographic and clinical features of patients with AIP type 1 and cardiovascular involvement.

N	Gender	Age	Type of AIP	Onset and Type of Vasculitis	Treatment	Smoking Status
1	male	75	Type 1	4 years after AIP diagnosis: asymmetric thickening of aorta wall (up till 5 mm) in infrarenal part of aorta	Rituximab and CST 10 mg	Former (30 PY)
2 *	male	66	Type 1	4 years after AIP diagnosis: thickening of aorta wall over the bifurcation	Azathioprine and CST 10 mg	Never
3	male	57	Type 1	At the time of AIP diagnosis: circumferential thickening of aorta wall	Rituximab	Never
4 *	male	66	Type 1	GPA 9 months after AIP: diagnosis with lung and bowel involvement	Rituximab and CST 2.5 mg	Never
5 *	female	65	Type 1	GPA 2 months after AIP: diagnosis with lung involvement	Rituximab	Never
6	male	65	Type 1	1 year after AIP diagnosis: mild thickening in infrarenal part of aorta	No treatment so far	Never
7	male	68	Type 1	3 months after AIP diagnosis: vasculitis in form of skin changes	Previously treated with CST and now hematologic treatment with lenalidomide (multiple myeloma)	Former (8 PY)
8 *	male	85	Type 1	At the time of AIP diagnosis: imaging signs of periaortitis	Previously treated with CST, currently no treatment	Former (10 PY)
9 *	female	24	Type 1	At the time of AIP diagnosis: eosinophilic myocarditis	Previously with CST, currently no treatment	Never
10 *	male	50	Type 1	5 years before AIP diagnosis: Churg Strauss syndrome, pericarditis and eosinophilic myocarditis, patients also had Erdheim Chester disease and hyper eosinophilic syndrome	Rituximab	Never

AIP-autoimmune pancreatitis; CST-corticosteroids; PY-pack-year; * patients also in Table 2; GPA-granulomatosis with polyangiitis (formerly known as Wegener’s granulomatosis); AIP NOS-autoimmune pancreatitis non-otherwise specified; age-age of patients at the time of AIP diagnosis.